GlassScriptPhysician profile
Seaver Lee Soon
NPI 1659301455
$59,366.81
in general payments reported to CMS, 2019-2025
21 companies · $1,433 in 2025
The $1,433 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15K · 2020: $6,601 · 2021: $30K · 2022: $1,347 · 2023: $2,994 · 2024: $1,939 · 2025: $1,433.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,975 · Travel and Lodging: $1,244 · Food and Beverage: $1,084 · Gift: $33.57 · Education: $28.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,975.00 |
| Travel and Lodging | $1,244.35 |
| Food and Beverage | $1,083.61 |
| Gift | $33.57 |
| Education | $28.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $23,190.46 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $20,593.11 | 2019-2024 | Libtayo, Dupixent |
| Merz North America, INC. | $8,252.03 | 2019-2022 | |
| Regeneron Pharmaceuticals, INC. | $2,760.00 | 2021 | |
| Abbvie INC. | $2,100.25 | 2024-2025 | |
| Journey Medical Corporation | $1,080.13 | 2025 | |
| Allergan, INC. | $346.38 | 2019 | |
| Galderma Laboratories, L.P. | $274.14 | 2019-2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $192.85 | 2019-2021 | |
| Celgene Corporation | $125.00 | 2019 | |
| Sanofi-Aventis U.S. LLC | $82.50 | 2019 | |
| Pfizer INC. | $74.49 | 2019-2020 | |
| Incyte Corporation | $51.80 | 2024-2025 | Opzelura |
| Vyne Pharmaceuticals INC. | $47.00 | 2020-2021 | |
| Leo Pharma INC. | $42.09 | 2019-2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $31.93 | 2020 | |
| Apyx Medical Corporation | $30.44 | 2019 | |
| Revance Therapeutics, INC. | $26.98 | 2024 | Daxxify |
| Dusa Pharmaceuticals, INC. | $24.80 | 2019 | |
| Janssen Biotech, INC. | $23.31 | 2025 | Tremfya |
| Almirall LLC | $17.12 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Seaver Soon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.